Nervous System Disorder Articles & Analysis
25 news found
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing product. The results ...
Next-generation Medtech innovator Kurve Therapeutics begins an equity crowdfunding journey with its $50 million Regulation A+ raise. Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases. Diseases like Dementia and Alzheimer’s afflict millions of people across the ...
Kurve Therapeutics, a next-generation medtech innovator focused on developing treatments for neurodegenerative diseases, announced it has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a $50 million funding round [kurvetx.com/offering-circular]. Investment opportunities are now open to public investors for offers starting at $580 for 100 ...
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population. Led by a team of experienced entrepreneurs with ...
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. Judith Ng Cashin, M.D., has joined the company as Chief Medical Officer effective as of October 1, 2018. "Dr. Ng Cashin has ...
PARIS, FRANCE, March 3, 2022, PRNewswire – Qynapse SAS, a medical technology company commercializing an FDA approved/CE cleared AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to announce that a symposium oral presentation and a poster presentation will be delivered at the upcoming AD/PD™ 2022 International Conference on ...
ByQynapse
Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors. The funds will be used to advance the company’s pioneering drug discovery ...
BOSTON, MA, February 14, 2022, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present 2 posters at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, on February 24-26, in West Palm Beach, FL. The posters ...
ByQynapse
BOSTON, MA, November 22, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-powered neuroimaging software platform for central nervous system (CNS) disorders, will unveil its new brand and latest AI developments as a key exhibitor in the AI Showcase at the 107th Radiology Society of North America (RSNA) Annual Meeting, from ...
ByQynapse
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Blackrock Neurotech for receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its groundbreaking MoveAgain Brain Computer Interface (BCI) system. There are an estimated ...
Group sales rise by 14.3 percent (Fx & portfolio adj.) to 9.781 billion euros / EBITDA before special items increases by 16.4 percent to 2.089 billion euros / Crop Science reports strong increase in sales and earnings / Pharmaceuticals and Consumer Health again post considerable sales growth / Core earnings per share advance by 29.6 percent to 1.05 euros / Net income at 85 million euros / ...
ByBayer AG
BOSTON, MA, November 4, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to sponsor the 14th Clinical Trials on Alzheimer’s Disease conference (CTAD) to be held from November 9-12, 2021, in Boston, MA. Qynapse will present new results on Qypredict®, ...
ByQynapse
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging the gut-brain axis for the discovery and development of small molecule therapeutics with an initial focus on autism spectrum disorder (ASD) and Parkinson’s disease (PD), today announced the appointment of A. Stewart Campbell, Ph.D. as Chief Executive Officer (CEO). Dr. Campbell will also serve as a ...
Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the appointment of Bryan Phillips as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary. ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference 2021. The session will become available for on-demand viewing at 6:00 a.m. ET on ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a keynote presentation at the ACCESS CHINA Forum @JPM WEEK 2021 Conference on Tuesday, January 5, 2021 at 8:00 PM EST. About Axial Therapeutics Axial ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on Tuesday, December 15, 2020 at 8:40 AM EST. About Axial ...
Axial R&D Leader to Chair Day-long Session on Clinical Trials for ASD and New Therapeutics Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that A. Stewart Campbell, Ph.D., Axial’s Senior Vice President of Research and ...
Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued patents in Switzerland (CH), Germany (DE), France (FR), United Kingdom (GB), Ireland (IE), Italy (IT), Spain (ES), Belgium (BE), Sweden (SE), ...
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 1:10 PM ET in New York, NY. About Axial Therapeutics Axial Therapeutics ...